. taking ustekinumab�a biologic that targets a different aspect of the immune system," gelfand said.
.
.
harvard medical school: "cgrp: a new era for migraine treatment."
.
yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital.
.
. taking ustekinumab�a biologic that targets a different aspect of the immune system," gelfand said.
.